GH Research PLC (NASDAQ: GHRS) announced the pricing of an underwritten offering of 6,527,779 ordinary shares at $18.00 per share, generating gross proceeds of approximately $117.5 million before deducting underwriting discounts and offering expenses.

The Dublin-based clinical-stage biopharmaceutical company expects the offering to close on April 30, 2026, subject to customary closing conditions. GH Research is offering all shares in the transaction.

Lynx1 Capital Management initiated the offering, with participation from Deep Track Capital and Foresite Capital, according to the company's statement.

Stifel, Cantor and RBC Capital Markets serve as joint book-running managers for the offering. Canaccord Genuity and Citizens Capital Markets act as co-lead managers.

The company filed a registration statement with the U.S. Securities and Exchange Commission, which was declared effective on March 7, 2025.

GH Research develops treatments for depression, with an initial focus on novel mebufotenin therapies for patients with treatment-resistant depression.